{"entity":{"id":"radioligand-dosimetry","kind":"technology","name":"Radioligand dosimetry","aka":[],"tldr":"Measuring, from scans taken after each dose, how much radiation a radioligand actually delivers to the tumour and to kidneys and marrow, so treatment can be personalised.","summary":"Radioligand therapies are mostly given at fixed activities, unlike external radiotherapy which is planned to a dose. Post-treatment SPECT or PET imaging at several time points lets physicists calculate absorbed doses to tumours and organs at risk, and trials are testing dose escalation guided by kidney and marrow dosimetry. European regulation now expects dosimetry to be available, and software and imaging protocols are being standardised to make it routine.","status":"established","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Dosimetry","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Dosimetry"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":["radioligand-therapy","lu177-radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":["spect"],"notes":[],"principle":"Serial quantitative imaging after administration measures activity in organs over time; time-integrated activity and dose kernels give absorbed dose per organ, which guides subsequent cycles.","strengths":["Personalises activity to each patient","Explains variable toxicity and response","Required by European regulation"],"limitations":["Extra imaging visits","Methodological variation between centres","Prospective outcome evidence still limited"]},"route":"/technologies/radioligand-dosimetry/","neighbours":{"technology":[{"id":"dota-chelation","kind":"technology","name":"DOTA chelation","route":"/technologies/dota-chelation/"},{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/"},{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/"},{"id":"monte-carlo-dosimetry","kind":"technology","name":"Monte Carlo dosimetry","route":"/technologies/monte-carlo-dosimetry/"},{"id":"quantitative-spect","kind":"technology","name":"Quantitative SPECT","route":"/technologies/quantitative-spect/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"},{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/"},{"id":"spect-dosimetry-workflow","kind":"technology","name":"SPECT dosimetry workflow for radionuclide therapy","route":"/technologies/spect-dosimetry-workflow/"},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"bottleneck":[{"id":"b-dosimetry-standardisation","kind":"bottleneck","name":"Dosimetry standardisation for radioligand therapy","route":"/bottlenecks/b-dosimetry-standardisation/"},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/"}],"section":[{"id":"f-dosimetry","kind":"section","name":"Dosimetry","route":"/fronts/f-dosimetry/"}],"idea":[{"id":"idea-ai-lesion-segmentation-dosimetry","kind":"idea","name":"AI segmentation to make voxel-level radioligand dosimetry practical at scale","route":"/ideas/idea-ai-lesion-segmentation-dosimetry/"},{"id":"idea-open-dosimetry-data-commons","kind":"idea","name":"An open data commons linking patient-level radiopharmaceutical dosimetry to outcomes","route":"/ideas/idea-open-dosimetry-data-commons/"},{"id":"idea-dosimetry-guided-dosing-standard","kind":"idea","name":"Kidney-dosimetry-guided dosing as the default for PSMA radioligand therapy","route":"/ideas/idea-dosimetry-guided-dosing-standard/"},{"id":"idea-tb161-instead-of-lu177","kind":"idea","name":"Terbium-161 instead of lutetium-177 in the same ligands","route":"/ideas/idea-tb161-instead-of-lu177/"}],"isotope":[{"id":"i-124","kind":"isotope","name":"Iodine-124","route":"/isotopes/i-124/"},{"id":"sc-44","kind":"isotope","name":"Scandium-44","route":"/isotopes/sc-44/"},{"id":"y-86","kind":"isotope","name":"Yttrium-86","route":"/isotopes/y-86/"}],"paper":[{"id":"paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022","kind":"paper","name":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","route":"/key-papers/paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022/"},{"id":"paper-sgouros-tat-review-nat-rev-2020","kind":"paper","name":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","route":"/key-papers/paper-sgouros-tat-review-nat-rev-2020/"},{"id":"paper-baum-prrt-1048-patients-oncotarget-2018","kind":"paper","name":"Results and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms","route":"/key-papers/paper-baum-prrt-1048-patients-oncotarget-2018/"}],"person":[{"id":"dale-bailey","kind":"person","name":"Dale L. Bailey","route":"/people/dale-bailey/"},{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","route":"/people/michael-lassmann/"}],"roadmap":[{"id":"dosimetry-roadmap","kind":"roadmap","name":"Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose","route":"/roadmaps/dosimetry-roadmap/"}],"term":[{"id":"absorbed-dose-term","kind":"term","name":"Absorbed dose and the gray (Gy)","route":"/terms/absorbed-dose-term/"},{"id":"activity-prescription","kind":"term","name":"Activity prescription: fixed versus dosimetry-guided dosing","route":"/terms/activity-prescription/"},{"id":"biological-half-life","kind":"term","name":"Biological half-life","route":"/terms/biological-half-life/"},{"id":"decay-correction","kind":"term","name":"Decay correction","route":"/terms/decay-correction/"},{"id":"effective-half-life","kind":"term","name":"Effective half-life","route":"/terms/effective-half-life/"},{"id":"equivalent-dose","kind":"term","name":"Equivalent dose and effective dose (sievert)","route":"/terms/equivalent-dose/"},{"id":"fixed-versus-personalised-dosing","kind":"term","name":"Fixed versus personalised (dosimetry-guided) dosing","route":"/terms/fixed-versus-personalised-dosing/"},{"id":"mird-formalism","kind":"term","name":"MIRD formalism","route":"/terms/mird-formalism/"},{"id":"partial-volume-effect","kind":"term","name":"Partial volume effect (PVE)","route":"/terms/partial-volume-effect/"},{"id":"time-activity-curve","kind":"term","name":"Time-activity curve (TAC)","route":"/terms/time-activity-curve/"}]}}